Implementation of clinical sequencing for molecular profiling in patients with advanced cancer

Autor:	Jiichiro Sasaki, Satoshi Igawa, Kazuto Nishio, Kazuhiko Nakagawa, Kazuko Sakai, Tomoya Fukui, Hisashi Mitsufuji, Katsuhiko Naoki, Mikiko Kakegawa, Takayuki Takahama, Masayuki Takeda
Rok vydání:	2021
Předmět:	Oncology Adult Male Cancer Research medicine.medical_specialty Genomics medicine.disease_cause DNA sequencing 03 medical and health sciences 0302 clinical medicine CDKN2A Internal medicine Neoplasms Genetics medicine Humans Multiplex RNA Neoplasm Lung cancer Gene 030304 developmental biology Aged Aged 80 and over 0303 health sciences business.industry Cancer High-Throughput Nucleotide Sequencing General Medicine DNA Neoplasm Genetic Profile Middle Aged medicine.disease 030220 oncology & carcinogenesis Feasibility Studies Female KRAS business
Zdroj:	Cancer biomarkers : section A of Disease markers. 31(2)
ISSN:	1875-8592
Popis:	BACKGROUND: The advancement of cancer genomics has allowed for multiplex gene assays using next-generation sequencing (NGS) to be practically implemented, however, a clinical practice system remains to be established. OBJECTIVE: We evaluated the feasibility of clinical sequencing using NGS-based multiplex gene assays between cooperating medical institutions in patients with advanced cancers. METHODS: In this observational study, DNA and RNA samples prepared from existing tumor tissues were subjected to comprehensive genomic profiling using targeted sequencing. RESULTS: From January 2017 to March 2019, 36 samples from 33 patients were assessed. Of all patients, 27 (82%) had lung cancer, with the median age of 50 years (range 38–83). Multiplex gene panel tests were successfully carried out on 35/36 (97%) samples. Potentially actionable gene alterations were identified in 10/30 (33%) samples (3 HER2, 2 KRAS, 2 ALK, 1 PIK3CA, 1 RET, and 1 CDKN2A). In the 6 samples examined for resistant mechanisms, ALK I1171N mutation and MET copy number gain were detected in 2 patients with ALK rearrangement-positive lung cancer. CONCLUSIONS: Clinical sequencing using NGS-based multiplex gene assays between collaborating domestic medical institutions was feasible, with a success rate of > 97%. Overall, clinical sequencing benefits therapeutic decision-making in patients with advanced cancer.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a390d98ee54fe53de178b1e702a3d8d2 https://pubmed.ncbi.nlm.nih.gov/33896820 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.